The goals of the Cytokine Core Facility of the CWRU CFAR are to provide members of the CFAR and CWRU research community access to the most modern techniques and expertise for measurement of cytokines, and to develop, test and apply novel methods for detection of cytokines and cytokine producing cells. Cytokines are critical mediators of the host response to infectious pathogens such as HIV-1 and M. tuberculosis, and cytokine biology is an essential component of much of the multidisciplinary AIDS research at CWRU. Studies range from investigations of cytokine dysregulation in HIV-1 and mycobacterial infection to cytokine immunotherapy and to determination of the roles of cytokines in host defense to HIV-1 and the opportunistic pathogens of advanced HIV-1 disease. The primary site of the Cytokine Core Facility is a dedicated 350 square foot laboratory in the biomedical research building (BRB) at CWRU. In addition, close interaction with the ACTG Immunology Advanced Technology Laboratory (ATL) and the Tuberculosis Research Unit (TBRU) at CWRU extend both the technical scope and capabilities of the cytokine core. The Cytokine Core Facility is unique and has no overlap with other core facilities at CWRU. The Cytokine Core has been critical to the following NIH-funded projects: Tuberculosis prevention and control (AI-43244, J.J. Ellner); A human model of protective immunity (AI-35207, J.J. Ellner); Heterogeneity of T cells in Mtb infection (AI-27243, W.H. Boom); Immunosuppression in mycobacterial disease (AI-18471, Z. Toossi); Expression of TB in the lung (HL-51630, E.A. Rich); Interaction of M tb. and HIV in the lung (HL-51536, Z. Toossi).

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI036219-06
Application #
6268180
Study Section
Project Start
1998-09-01
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
6
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216
Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552

Showing the most recent 10 out of 539 publications